These findings and the current study on the influence of MAO-B and oxidative stress on PD determined the aim of this research, pointed to in silico evaluation and in vitro determination of the effects of series N-pyrrolyl hydrazide–hydrazones as potential neuroprotective agents and MAO-B inhibitors as possible combined effects included in the PD treatment. This evidence concerns the gene MAOB and Parkinson disease.